Publications by authors named "M J Bertran"
Background: Pneumococcal infections are associated with significant morbidity and mortality, especially at the extremes of age and in those with underlying conditions. Little is known about the risks, presentations or outcomes of invasive pneumococcal disease (IPD) during pregnancy or the postpartum period.
Methods: The UK Health Security Agency conducts enhanced national surveillance of IPD in England.
Peptidylarginine deiminase IV (PADI4, PAD4) deregulation promotes the development of autoimmunity, cancer, atherosclerosis and age-related tissue fibrosis. PADI4 additionally mediates immune responses and cellular reprogramming, although the full extent of its physiological roles is unexplored. Despite detailed molecular knowledge of PADI4 activation in vitro, we lack understanding of its regulation within cells, largely due to a lack of appropriate systems and tools.
View Article and Find Full Text PDFArticle Synopsis
- The UK shifted to a 1+1 infant immunization schedule for the PCV13 vaccine starting January 1, 2020, and a study analyzed its impact on invasive pneumococcal disease (IPD) in children aged 0-3 years.
- A comparison was made between a birth cohort eligible for the new 1+1 schedule and historical cohorts under the previous 2+1 schedule, examining various metrics like incidence rates and clinical outcomes.
- Findings showed no significant differences in IPD incidence, disease characteristics, or outcomes between the 1+1 and 2+1 cohorts after three years, indicating the new schedule did not adversely affect health outcomes in eligible children.
Structural insight into the function of human peptidyl arginine deiminase 6.
Comput Struct Biotechnol J
December 2024
Peptidyl arginine deiminase 6 (PADI6 or PAD6) is vital for early embryonic development in mice and humans, yet its function remains elusive. PADI6 is less conserved than other PADIs and it is currently unknown whether it has a catalytic function. Here we show that human PADI6 dimerises like hPADIs 2-4, however, does not bind Ca and is inactive in assays against standard PADI substrates.
View Article and Find Full Text PDFCombiVacS study has demonstrated a strong immune response of the heterologous ChAdOx1-S/BNT162b2 vaccine combination. The primary outcomes of the study were to assess the humoral immune response against SARS-CoV-2, 28 days after a third dose of a mRNA vaccine, in subjects that received a previous prime-boost scheme with ChAdOx1-S/BNT162b2. Secondary outcomes extended the study to 3 and 6 months.
View Article and Find Full Text PDF